These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29093275)

  • 1. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.
    Dominguez C; McCampbell KK; David JM; Palena C
    JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
    Kajihara N; Kobayashi T; Otsuka R; Nio-Kobayashi J; Oshino T; Takahashi M; Imanishi S; Hashimoto A; Wada H; Seino KI
    Cancer Immunol Immunother; 2023 Apr; 72(4):851-864. PubMed ID: 36104597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer.
    Kumar S; Wilkes DW; Samuel N; Blanco MA; Nayak A; Alicea-Torres K; Gluck C; Sinha S; Gabrilovich D; Chakrabarti R
    J Clin Invest; 2018 Nov; 128(11):5095-5109. PubMed ID: 30295647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer.
    Wang G; Romero Y; Thevarajan I; Zolkiewska A
    Oncoimmunology; 2023; 12(1):2158006. PubMed ID: 36545255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
    Front Immunol; 2019; 10():804. PubMed ID: 31105691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer.
    Ngule C; Shi R; Ren X; Jia H; Oyelami F; Li D; Park Y; Kim J; Hemati H; Zhang Y; Xiong X; Shinkle A; Vanderford NL; Bachert S; Zhou BP; Wang J; Song J; Liu X; Yang JM
    Mol Cancer; 2024 Sep; 23(1):188. PubMed ID: 39243032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA Uc003xsl.1-Mediated Activation of the NFκB/IL8 Axis Promotes Progression of Triple-Negative Breast Cancer.
    Xu Y; Ren W; Li Q; Duan C; Lin X; Bi Z; You K; Hu Q; Xie N; Yu Y; Xu X; Hu H; Yao H
    Cancer Res; 2022 Feb; 82(4):556-570. PubMed ID: 34965935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
    Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z
    Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer.
    Yu B; Luo F; Sun B; Liu W; Shi Q; Cheng SY; Chen C; Chen G; Li Y; Feng H
    Adv Sci (Weinh); 2021 Oct; 8(20):e2100014. PubMed ID: 34392614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
    Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
    Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
    Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
    Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
    Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
    Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
    [No Abstract]   [Full Text] [Related]  

  • 13. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
    Bilusic M; Heery CR; Collins JM; Donahue RN; Palena C; Madan RA; Karzai F; Marté JL; Strauss J; Gatti-Mays ME; Schlom J; Gulley JL
    J Immunother Cancer; 2019 Sep; 7(1):240. PubMed ID: 31488216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
    Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
    Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
    Zonneville J; Colligan S; Grant S; Miller A; Wallace P; Abrams SI; Bakin AV
    Int J Cancer; 2020 Oct; 147(8):2279-2292. PubMed ID: 32452014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.